EA Pharma

Focus: EA Pharma is a Japan-based pharmaceutical company specializing in amino acid treatments with a focus on immunology and metabolic diseases. The company operates a diversified pipeline across gastroenterology, bone health, and immune-mediated conditions.

Immunology Metabolic Diseases

Profile data last refreshed 24m ago · AI intelligence enriched 2w ago

Open Jobs

About EA Pharma

AI assessmentNot Hiring

No open roles listed right now. Follow EA Pharma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Placebo

Healthy Male Volunteers

Phase 1

Clinical Trials (1)

NCT03014895A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects

Phase 1

Help build intelligence for EA Pharma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio spans multiple therapeutic areas with 13 active clinical trials including Phase 3 programs in ulcerative colitis (AJM300) and chronic constipation (AJG555)
Focused specialty in amino acid treatments offers a differentiated scientific niche with limited direct competition
Japan-based company with global pipeline exposure provides international career trajectory opportunities in an underrepresented geography for pharma talent

Watch Out For

Zero active job openings signals either lean operations or potential hiring freeze, making near-term employment entry challenging
Minimal published data on financials, funding, employee count, and recent milestones creates transparency risk and makes company health assessment difficult

Generated by Claude from EA Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

E6130

Japanese Healthy Adult Male Participants

Phase 1

Clinical Trials (1)

NCT02902978A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects

Phase 1

E3112

Healthy Male Participants

Phase 1

Clinical Trials (1)

NCT03922633A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants

Phase 1

EA1080

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT04223960A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants

Phase 1

E6130

Healthy Participants

Phase 1

Clinical Trials (1)

NCT03390647A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants

Phase 1

AJM347

Healthy Participants

Phase 1

Clinical Trials (1)

NCT03133468Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State

Phase 1

[14C]-E6007

Healthy Male Participants

Phase 1

Clinical Trials (1)

NCT03444818A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants

Phase 1

E6011 2 mg/kg

Crohn's Disease

Phase 1/2

Clinical Trials (1)

NCT02039063A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease

Phase 1/2

E6011

Primary Biliary Cholangitis

Phase 2

Clinical Trials (1)

NCT03092765Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid